Soberana Plus

File:Soberana Plus vaccine logo.png

Soberana_Plus_vaccine_logo.png

Soberana Plus is a COVID-19 vaccine developed by the Finlay Institute in Cuba. It is part of the Soberana vaccine family, which includes Soberana 01 and Soberana 02. Soberana Plus is designed as a booster dose to enhance the immune response in individuals who have previously been vaccinated with other COVID-19 vaccines or have recovered from a COVID-19 infection.

Development

The development of Soberana Plus began in response to the global COVID-19 pandemic. The Finlay Institute, a leading Cuban biomedical research organization, spearheaded the project. The vaccine is based on a recombinant protein subunit platform, which uses a part of the SARS-CoV-2 virus to stimulate an immune response without causing the disease.

Clinical Trials

Soberana Plus underwent several phases of clinical trials to evaluate its safety and efficacy. The trials included participants who had previously received other COVID-19 vaccines or had recovered from COVID-19. The results indicated that Soberana Plus significantly boosted the immune response, providing enhanced protection against the virus.

Approval and Distribution

The Cuban regulatory authorities granted emergency use authorization for Soberana Plus after reviewing the clinical trial data. The vaccine has been distributed within Cuba and to several other countries as part of international cooperation efforts. The distribution strategy focuses on using Soberana Plus as a booster dose to complement other vaccination programs.

Mechanism of Action

Soberana Plus works by introducing a recombinant protein subunit of the SARS-CoV-2 virus into the body. This protein is recognized by the immune system, which then produces antibodies and activates T-cells to fight the virus. The booster dose enhances the immune memory, providing longer-lasting protection against COVID-19.

Efficacy

Studies have shown that Soberana Plus is effective in boosting the immune response in individuals who have been previously vaccinated or have recovered from COVID-19. The vaccine has demonstrated a good safety profile with minimal side effects.

See Also

• COVID-19 vaccine
• Soberana 01
• Soberana 02
• Finlay Institute
• SARS-CoV-2
• T-cells